drug · small molecule

TRUQAP

updated 3mo ago

by $AZN ASTRAZENECA PLC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 7

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 7 investigational indications.

targets

Serine/threonine-protein kinase AKT

all catalysts(0)

nothing on the calendar yet

Trials studying TRUQAP

phase2Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancerrecruitingn=315
phase1A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Canceractive not recruitingn=138
phase3Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancerrecruitingn=540
phase2Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Canceractive not recruitingn=435
phase2Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumorsrecruitingn=92
phase2A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Canceractive not recruitingn=243
phase3Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)recruitingn=895
phase1A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participantsrecruitingn=42

more trials →

News(5)

Vaderis hauls in $152M to test an AKT-targeting drug
The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
biopharma_dive · 3d ago
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
biospace · 11d ago
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
biopharma_dive · 2mo ago
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
Capivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.
onclive · 3mo ago
Celcuity strengthens case for ASCO-spotlighted breast cancer drug
The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.
biopharma_dive · 3mo ago

brand

TRUQAP

trade names

Truqap

generic

CAPIVASERTIB

MOA

12.1 Mechanism of Action Capivasertib is an inhibitor of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2 and AKT3) and inhibits phosphorylation of downstream AKT substrates. AKT activation in tumors is a result of activation of upstream signaling pathways, mutations in AKT1 , loss of phosphatase and tensin homolog (PTEN) function and mutations in the catalytic subunit alpha of phosphatidylinositol 3-kinase ( PIK3CA ). In vitro , capivasertib reduced growth of breast cancer cell lines including those with relevant PIK3CA or AKT1 mutations or PTEN alteration. In vivo , capivasertib alone and in combination with fulvestrant inhibited tumor growth of mouse xenograft models including estrogen receptor positive breast cancer models with alterations in PIK3CA, AKT1 , and PTEN .

indication

1 INDICATIONS AND USAGE TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN -alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN -alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. (1)

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 34m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

TRUQAP

updated 3mo ago

by $AZN ASTRAZENECA PLC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 7

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 7 investigational indications.

targets

Serine/threonine-protein kinase AKT

all catalysts(0)

nothing on the calendar yet

Trials studying TRUQAP

phase2Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancerrecruitingn=315
phase1A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Canceractive not recruitingn=138
phase3Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancerrecruitingn=540
phase2Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Canceractive not recruitingn=435
phase2Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumorsrecruitingn=92
phase2A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Canceractive not recruitingn=243
phase3Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)recruitingn=895
phase1A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participantsrecruitingn=42

more trials →

News(5)

Vaderis hauls in $152M to test an AKT-targeting drug
The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
biopharma_dive · 3d ago
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
biospace · 11d ago
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
biopharma_dive · 2mo ago
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
Capivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.
onclive · 3mo ago
Celcuity strengthens case for ASCO-spotlighted breast cancer drug
The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.
biopharma_dive · 3mo ago

brand

TRUQAP

trade names

Truqap

generic

CAPIVASERTIB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 34m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

TRUQAP

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TRUQAP

News(5)

Report a data issue

comments(0)

TRUQAP

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TRUQAP

News(5)

Report a data issue

comments(0)